{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:42Z","timestamp":1787003442587,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Systemic sclerosis (SSc or scleroderma) is an auto-immune disease characterized by skin fibrosis. While primary cells from patients are considered as a unique resource to better understand human disease biology, the effect of\n                    <jats:italic>in vitro<\/jats:italic>\n                    culture on these cells and their evaluation as a platform to identify disease regulators remain poorly characterized. The goal of our studies was to provide insights into the utility of SSc dermal fibroblast primary cells for therapeutic target discovery. The disease phenotypes of freshly isolated and\n                    <jats:italic>in vitr<\/jats:italic>\n                    o cultured SSc dermal fibroblasts were characterized using whole transcriptome profiling, alpha smooth muscle actin (ASMA) expression and cell impedance. SSc dermal fibroblasts retained most of the molecular disease phenotype upon\n                    <jats:italic>in vitro<\/jats:italic>\n                    culture for at least four cell culture passages (approximatively 10 cell doublings). We validated an RNA interference high throughput assay that successfully identified genes affecting the myofibroblast phenotype of SSc skin fibroblasts. These genes included\n                    <jats:italic>MKL1<\/jats:italic>\n                    ,\n                    <jats:italic>RHOA<\/jats:italic>\n                    and\n                    <jats:italic>LOXL2 that<\/jats:italic>\n                    were previously proposed as therapeutic anti-fibrotic target, and\n                    <jats:italic>ITGA5<\/jats:italic>\n                    , that has been less studied in fibrosis biology and may be a novel potential modifier of SSc fibroblast biology. Together our results demonstrated the value of carefully-phenotyped SSc dermal fibroblasts as a platform for SSc target and drug discovery.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-41153-w","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:06:06Z","timestamp":1552550766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Loubna","family":"Chadli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Sotthewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan N.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Cahir-McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Dorj\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-4200","authenticated-orcid":false,"given":"Jeroen","family":"DeGroot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L.","family":"Viney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Aarbiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Gardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"41153_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 51, 1017\u201326 (2012).","journal-title":"Rheumatology (Oxford)."},{"key":"41153_CR2","doi-asserted-by":"publisher","unstructured":"Cossu, M., Beretta, L., Mosterman, P., de Hair, M. J. H. & Radstake, T. R. D. J. Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist\u2019s, Clinician\u2019s, and Patient\u2019s Perspective. Clin. Rev. Allergy Immunol., https:\/\/doi.org\/10.1007\/s12016-017-8636-1 (2017).","DOI":"10.1007\/s12016-017-8636-1"},{"key":"41153_CR3","doi-asserted-by":"publisher","unstructured":"Schulz, J.-N. et al. New developments on skin fibrosis - Essential signals emanating from the extracellular matrix for the control of myofibroblasts. Matrix Biol. https:\/\/doi.org\/10.1016\/j.matbio.2018.01.025 (2018).","DOI":"10.1016\/j.matbio.2018.01.025"},{"key":"41153_CR4","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1002\/art.22186","volume":"54","author":"EY Kissin","year":"2006","unstructured":"Kissin, E. Y., Merkel, P. A. & Lafyatis, R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 54, 3655\u201360 (2006).","journal-title":"Arthritis Rheum."},{"key":"41153_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/1523-1747.ep12462561","volume":"90","author":"JS Perlish","year":"1988","unstructured":"Perlish, J. S., Lemlich, G. & Fleischmajer, R. Identification of collagen fibrils in scleroderma skin. J. Invest. Dermatol. 90, 48\u201354 (1988).","journal-title":"J. Invest. Dermatol."},{"key":"41153_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/art.21894","volume":"54","author":"H Gardner","year":"2006","unstructured":"Gardner, H. et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum. 54, 1961\u201373 (2006).","journal-title":"Arthritis Rheum."},{"key":"41153_CR7","doi-asserted-by":"publisher","first-page":"12319","DOI":"10.1073\/pnas.1635114100","volume":"100","author":"ML Whitfield","year":"2003","unstructured":"Whitfield, M. L. et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl. Acad. Sci. USA 100, 12319\u201324 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41153_CR8","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/jid.2013.130","volume":"133","author":"M Hinchcliff","year":"2013","unstructured":"Hinchcliff, M. et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J. Invest. Dermatol. 133, 1979\u201389 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"41153_CR9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1002\/art.39289","volume":"67","author":"S Assassi","year":"2015","unstructured":"Assassi, S. et al. Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. Arthritis Rheumatol. (Hoboken, N.J.) 67, 3016\u201326 (2015).","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"41153_CR10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/jid.2011.472","volume":"132","author":"SA Pendergrass","year":"2012","unstructured":"Pendergrass, S. A. et al. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J. Invest. Dermatol. 132, 1363\u201373 (2012).","journal-title":"J. Invest. Dermatol."},{"key":"41153_CR11","doi-asserted-by":"publisher","first-page":"e1004005","DOI":"10.1371\/journal.pcbi.1004005","volume":"11","author":"JM Mahoney","year":"2015","unstructured":"Mahoney, J. M. et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput. Biol. 11, e1004005 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"41153_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0417-1","volume":"9","author":"JN Taroni","year":"2017","unstructured":"Taroni, J. N. et al. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med. 9, 27 (2017).","journal-title":"Genome Med."},{"key":"41153_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/jid.2009.318","volume":"130","author":"JL Sargent","year":"2010","unstructured":"Sargent, J. L. et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J. Invest. Dermatol. 130, 694\u2013705 (2010).","journal-title":"J. Invest. Dermatol."},{"key":"41153_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2741\/s22","volume":"1","author":"J Varga","year":"2009","unstructured":"Varga, J. & Whitfield, M. L. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front. Biosci. (Schol. Ed). 1, 226\u201335 (2009).","journal-title":"Front. Biosci. (Schol. Ed)."},{"key":"41153_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/art.20871","volume":"52","author":"FK Tan","year":"2005","unstructured":"Tan, F. K. et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum. 52, 865\u201376 (2005).","journal-title":"Arthritis Rheum."},{"key":"41153_CR16","unstructured":"Fuzii, H. T. et al. Affected and non-affected skin fibroblasts from systemic sclerosis patients share a gene expression profile deviated from the one observed in healthy individuals. Clin. Exp. Rheumatol. 26, 866\u201374 (2008)."},{"key":"41153_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2230.2011.04254.x","volume":"37","author":"L Zhu","year":"2012","unstructured":"Zhu, L., Gao, D., Yang, J. & Li, M. Characterization of the phenotype of high collagen-producing fibroblast clones in systemic sclerosis, using a new modified limiting-dilution method. Clin. Exp. Dermatol. 37, 395\u2013403 (2012).","journal-title":"Clin. Exp. Dermatol."},{"key":"41153_CR18","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/1529-0131(200108)44:8<1855::AID-ART324>3.0.CO;2-Q","volume":"44","author":"DD Wallis","year":"2001","unstructured":"Wallis, D. D. et al. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum. 44, 1855\u201364 (2001).","journal-title":"Arthritis Rheum."},{"key":"41153_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/art.11157","volume":"48","author":"Y Mori","year":"2003","unstructured":"Mori, Y., Chen, S.-J. & Varga, J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. 48, 1964\u201378 (2003).","journal-title":"Arthritis Rheum."},{"key":"41153_CR20","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0002-9440(10)63215-4","volume":"164","author":"Y Asano","year":"2004","unstructured":"Asano, Y., Ihn, H., Yamane, K., Kubo, M. & Tamaki, K. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am. J. Pathol. 164, 1275\u201392 (2004).","journal-title":"Am. J. Pathol."},{"key":"41153_CR21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0002-9440(10)61252-7","volume":"167","author":"Y Chen","year":"2005","unstructured":"Chen, Y. et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta\/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK\/ERK: insights into pathological scarring in chronic fibrotic disease. Am. J. Pathol. 167, 1699\u2013711 (2005).","journal-title":"Am. J. Pathol."},{"key":"41153_CR22","doi-asserted-by":"publisher","first-page":"e0126015","DOI":"10.1371\/journal.pone.0126015","volume":"10","author":"X Shiwen","year":"2015","unstructured":"Shiwen, X. et al. A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS One 10, e0126015 (2015).","journal-title":"PLoS One"},{"key":"41153_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.21725","volume":"54","author":"Y Chen","year":"2006","unstructured":"Chen, Y. et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum. 54, 1309\u201316 (2006).","journal-title":"Arthritis Rheum."},{"key":"41153_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3899\/jrheum.111132","volume":"39","author":"A Antonelli","year":"2012","unstructured":"Antonelli, A. et al. Systemic sclerosis fibroblasts show specific alterations of interferon-\u03b3 and tumor necrosis factor-\u03b1-induced modulation of interleukin 6 and chemokine ligand 2. J. Rheumatol. 39, 979\u201385 (2012).","journal-title":"J. Rheumatol."},{"key":"41153_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/03009742.2011.585349","volume":"40","author":"A Antonelli","year":"2011","unstructured":"Antonelli, A. et al. IFN-\u03b3 and TNF-\u03b1 induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. Scand. J. Rheumatol. 40, 453\u20136 (2011).","journal-title":"Scand. J. Rheumatol."},{"key":"41153_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fphar.2017.00855","volume":"8","author":"X Li","year":"2017","unstructured":"Li, X., Zhu, L., Wang, B., Yuan, M. & Zhu, R. Drugs and Targets in Fibrosis. Front. Pharmacol. 8, 855 (2017).","journal-title":"Front. Pharmacol."},{"key":"41153_CR27","unstructured":"Garret, S. M., Frost, D. B. & Feghali-Bostwick, C. The mighty fibroblast and its utility in scleroderma research. J. scleroderma Relat. Disord. 2, 69\u2013134."},{"key":"41153_CR28","doi-asserted-by":"publisher","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","volume":"3","author":"A Milano","year":"2008","unstructured":"Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3, e2696 (2008).","journal-title":"PLoS One"},{"key":"41153_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/rheumatology\/ker367","volume":"51","author":"J Frost","year":"2012","unstructured":"Frost, J. et al. Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. Rheumatology (Oxford). 51, 1049\u201352 (2012).","journal-title":"Rheumatology (Oxford)."},{"key":"41153_CR30","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1172\/JCI74929","volume":"125","author":"R Kramann","year":"2015","unstructured":"Kramann, R. et al. Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J. Clin. Invest. 125, 2935\u201351 (2015).","journal-title":"J. Clin. Invest."},{"key":"41153_CR31","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.3748\/wjg.15.3246","volume":"15","author":"L-X Liu","year":"2009","unstructured":"Liu, L.-X. et al. Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro. World J. Gastroenterol. 15, 3246\u201353 (2009).","journal-title":"World J. Gastroenterol."},{"key":"41153_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.addr.2017.07.010","volume":"121","author":"S Yazdani","year":"2017","unstructured":"Yazdani, S., Bansal, R. & Prakash, J. Drug targeting to myofibroblasts: Implications for fibrosis and cancer. Adv. Drug Deliv. Rev. 121, 101\u2013116 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"41153_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1165\/rcmb.2014-0468OC","volume":"54","author":"SH Wettlaufer","year":"2016","unstructured":"Wettlaufer, S. H., Scott, J. P., McEachin, R. C., Peters-Golden, M. & Huang, S. K. Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation. Am. J. Respir. Cell Mol. Biol. 54, 114\u201327 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"41153_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcb.240280204","volume":"28","author":"T Vuorio","year":"1985","unstructured":"Vuorio, T., M\u00e4kel\u00e4, J. K. & Vuorio, E. Activation of type I collagen genes in cultured scleroderma fibroblasts. J. Cell. Biochem. 28, 105\u201313 (1985).","journal-title":"J. Cell. Biochem."},{"key":"41153_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11926-009-0017-1","volume":"11","author":"B Hinz","year":"2009","unstructured":"Hinz, B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr. Rheumatol. Rep. 11, 120\u20136 (2009).","journal-title":"Curr. Rheumatol. Rep."},{"key":"41153_CR36","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1101\/gr.1332603","volume":"13","author":"G-J Arts","year":"2003","unstructured":"Arts, G.-J. et al. Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res. 13, 2325\u201332 (2003).","journal-title":"Genome Res."},{"key":"41153_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1124\/jpet.114.213520","volume":"349","author":"AJ Haak","year":"2014","unstructured":"Haak, A. J. et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor\/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J. Pharmacol. Exp. Ther. 349, 480\u20136 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"41153_CR38","doi-asserted-by":"publisher","first-page":"16850","DOI":"10.1073\/pnas.1316764110","volume":"110","author":"LS Velasquez","year":"2013","unstructured":"Velasquez, L. S. et al. Activation of MRTF-A-dependent gene expression with a small molecule promotes myofibroblast differentiation and wound healing. Proc. Natl. Acad. Sci. USA 110, 16850\u20135 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41153_CR39","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1172\/JCI66700","volume":"123","author":"Y Zhou","year":"2013","unstructured":"Zhou, Y. et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Invest. 123, 1096\u2013108 (2013).","journal-title":"J. Clin. Invest."},{"key":"41153_CR40","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1096\/fasebj.6.7.1348714","volume":"6","author":"K Reiser","year":"1992","unstructured":"Reiser, K., McCormick, R. J. & Rucker, R. B. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J. 6, 2439\u201349 (1992).","journal-title":"FASEB J."},{"key":"41153_CR41","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm.2208","volume":"16","author":"V Barry-Hamilton","year":"2010","unstructured":"Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009\u201317 (2010).","journal-title":"Nat. Med."},{"key":"41153_CR42","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","volume":"66","author":"N Ikenaga","year":"2017","unstructured":"Ikenaga, N. et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 66, 1697\u20131708 (2017).","journal-title":"Gut"},{"key":"41153_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00141013","volume":"43","author":"JW Chien","year":"2014","unstructured":"Chien, J. W. et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 43, 1430\u20138 (2014).","journal-title":"Eur. Respir. J."},{"key":"41153_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","volume":"5","author":"G Raghu","year":"2017","unstructured":"Raghu, G. et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet. Respir. Med. 5, 22\u201332 (2017).","journal-title":"Lancet. Respir. Med."},{"key":"41153_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1365-2133.1995.tb02743.x","volume":"133","author":"M Chanoki","year":"1995","unstructured":"Chanoki, M. et al. Increased expression of lysyl oxidase in skin with scleroderma. Br. J. Dermatol. 133, 710\u20135 (1995).","journal-title":"Br. J. Dermatol."},{"key":"41153_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/art.38277","volume":"66","author":"D Rimar","year":"2014","unstructured":"Rimar, D. et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol. (Hoboken, N.J.) 66, 726\u201330 (2014).","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"41153_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fphar.2013.00159","volume":"4","author":"A Gardet","year":"2013","unstructured":"Gardet, A., Zheng, T. S. & Viney, J. L. Genetic architecture of human fibrotic diseases: disease risk and disease progression. Front. Pharmacol. 4, 159 (2013).","journal-title":"Front. Pharmacol."},{"key":"41153_CR48","doi-asserted-by":"publisher","first-page":"15136","DOI":"10.1073\/pnas.1520997112","volume":"112","author":"R Saigusa","year":"2015","unstructured":"Saigusa, R. et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proc. Natl. Acad. Sci. USA 112, 15136\u201341 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41153_CR49","doi-asserted-by":"publisher","first-page":"e0151999","DOI":"10.1371\/journal.pone.0151999","volume":"11","author":"D Weihrauch","year":"2016","unstructured":"Weihrauch, D. et al. An IRF5 Decoy Peptide Reduces Myocardial Inflammation and Fibrosis and Improves Endothelial Cell Function in Tight-Skin Mice. PLoS One 11, e0151999 (2016).","journal-title":"PLoS One"},{"key":"41153_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cancers5010027","volume":"5","author":"F Schaffner","year":"2013","unstructured":"Schaffner, F., Ray, A. M. & Dontenwill, M. Integrin \u03b15\u03b21, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers (Basel). 5, 27\u201347 (2013).","journal-title":"Cancers (Basel)."},{"key":"41153_CR51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/01.ASN.0000051600.53134.B9","volume":"14","author":"BS Weston","year":"2003","unstructured":"Weston, B. S., Wahab, N. A. & Mason, R. M. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J. Am. Soc. Nephrol. 14, 601\u201310 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"41153_CR52","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jaci.2007.12.1159","volume":"121","author":"LM Moir","year":"2008","unstructured":"Moir, L. M., Burgess, J. K. & Black, J. L. Transforming growth factor beta 1 increases fibronectin deposition through integrin receptor alpha 5 beta 1 on human airway smooth muscle. J. Allergy Clin. Immunol. 121, 1034\u20139.e4 (2008).","journal-title":"J. Allergy Clin. Immunol."},{"key":"41153_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1465-9921-7-2","volume":"7","author":"G Chen","year":"2006","unstructured":"Chen, G. & Khalil, N. TGF-beta1 increases proliferation of airway smooth muscle cells by phosphorylation of map kinases. Respir. Res. 7, 2 (2006).","journal-title":"Respir. Res."},{"key":"41153_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.fct.2017.07.014","volume":"107","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Dioscin, a potent ITGA5 inhibitor, reduces the synthesis of collagen against liver fibrosis: Insights from SILAC-based proteomics analysis. Food Chem. Toxicol. 107, 318\u2013328 (2017).","journal-title":"Food Chem. Toxicol."},{"key":"41153_CR55","doi-asserted-by":"crossref","unstructured":"Gordon, G. M. et al. A cell-based screening assay to identify pharmaceutical compounds that enhance the regenerative quality of corneal repair. Wound Repair Regen. 24, 89\u201399 (2016).","DOI":"10.1111\/wrr.12390"},{"key":"41153_CR56","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1073\/pnas.1702750114","volume":"114","author":"MJ Bollong","year":"2017","unstructured":"Bollong, M. J. et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc. Natl. Acad. Sci. USA 114, 4679\u20134684 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"41153_CR57","doi-asserted-by":"publisher","unstructured":"Oh, R. S. et al. RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation. J. Cell Sci., https:\/\/doi.org\/10.1242\/jcs.209932 (2018).","DOI":"10.1242\/jcs.209932"},{"key":"41153_CR58","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).","journal-title":"Nucleic Acids Res."},{"key":"41153_CR59","volume":"2","author":"C Li","year":"2001","unstructured":"Li, C. & Hung Wong, W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2, RESEARCH0032 (2001).","journal-title":"Genome Biol."},{"key":"41153_CR60","doi-asserted-by":"crossref","unstructured":"Gentleman, R., Carey, V., Huber, W., Irizarry, R. A. & Dudoit, S. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Springer Sci. Media (2005).","DOI":"10.1007\/0-387-29362-0"},{"key":"41153_CR61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u201327 (2007).","journal-title":"Biostatistics"},{"key":"41153_CR62","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"41153_CR63","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"B Yoav","year":"1995","unstructured":"Yoav, B. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57, 289\u2013300 (1995).","journal-title":"J R Stat Soc B"},{"key":"41153_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).","journal-title":"BMC Bioinformatics"},{"key":"41153_CR65","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u20137 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41153-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T16:07:48Z","timestamp":1721059668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41153-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41153-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.L., E.C.M., P.C., J.L.V., T.S.Z. and A.G. are current or former employees of Biogen and shareholders. L.C., B.S., S.N.A., M.C., D.F.F., J.D. and J.A. are current or former employees of Charles River, a contract research organization. D.F.F. is a shareholder of Charles River. The authors, including A.D., J.d.V.B. and T.W.J.H. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4521"}}